A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

AIMS: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibit...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Eur Heart J
Main Authors: McMurray, John, Packer, Milton, Desai, Akshay, Gong, Jianjian, Greenlaw, Nicola, Lefkowitz, Martin, Rizkala, Adel, Shi, Victor, Rouleau, Jean, Solomon, Scott, Swedberg, Karl, Zile, Michael R., Andersen, Karl, Arango, Juan Luis, Arnold, Malcolm, Be˘lohlávek, Jan, Böhm, Michael, Boytsov, Sergey, Burgess, Lesley, Cabrera, Walter, Chen, Chen-Huan, Erglis, Andrejs, Fu, Michael, Gomez, Efrain, Gonzalez, Angel, Hagege, Albert-Alain, Katova, Tzvetana, Kiatchoosakun, Songsak, Kim, Kee-Sik, Bayram, Edmundo, Martinez, Felipe, Merkely, Bela, Mendoza, Iván, Mosterd, Arend, Negrusz-Kawecka, Marta, Peuhkurinen, Keijo, Ramires, Felix, Refsgaard, Jens, Senni, Michele, Sibulo, Antonio S., Silva-Cardoso, José, Squire, Iain, Starling, Randall C., Vinereanu, Dragos, Teerlink, John R., Wong, Raymond
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2015
נושאים:
FASTTrack Clinical Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4328198/
https://ncbi.nlm.nih.gov/pubmed/25416329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu455
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים